|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou J, Xu Y, Liu J, Feng L, Yu J and Chen
D: Global burden of lung cancer in 2022 and projections to 2050:
Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol.
93:1026932024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Timmerman RD, Hu C, Michalski JM, Bradley
JC, Galvin J, Johnstone DW and Choy H: Long-term results of
stereotactic body radiation therapy in medically inoperable stage I
non-small cell lung cancer. JAMA Oncol. 4:1287–1288. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park HS, Detterbeck FC, Madoff DC, Bade
BC, Kumbasar U, Mase VJ Jr, Li AX, Blasberg JD, Woodard GA, Brandt
WS and Decker RH: A guide for managing patients with stage I NSCLC:
Deciding between lobectomy, segmentectomy, wedge, SBRT and
ablation-part 4: Systematic review of evidence involving SBRT and
ablation. J Thorac Dis. 14:2412–2436. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang JY, Senan S, Paul MA, Mehran RJ,
Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al:
Stereotactic ablative radiotherapy versus lobectomy for operable
stage I non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Oncol. 16:630–637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
JoLT-Ca Sublobar Resection (SR) Versus
Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
(STABLE-MATES). ClinicalTrials.gov. Available from:. https://clinicaltrials.gov/study/NCT02468024October
7–2024
|
|
7
|
Kong FM, Yu J, Dignam JJ, Xing L, Hu C,
Xiao Y, Yin Y, Chang A, Orringer M, D'Amico T, et al: A phase II
randomized trial of radical resection vs stereotactic body
radiation therapy (SBRT) in patients with operable stage I
non-small cell lung cancer (NSCLC): Final report Of RTOG-F3502. Int
J Radiat Oncol Biol Phys. 120 (Suppl 1):S105–S106. 2024. View Article : Google Scholar
|
|
8
|
Ritter TA, Timmerman RD, Hanfi HI, Shi H,
Leiner MK, Feng H, Skinner VL, Robin LM, Odle C, Amador G, et al:
Centralized quality assurance of stereotactic body radiation
therapy for the veterans affairs cooperative studies program study
number 2005: A phase 3 randomized trial of lung cancer surgery or
stereotactic radiotherapy for operable early-stage non-small cell
lung cancer (VALOR). Pract Radiat Oncol. 15:e29–e39. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schneider BJ, Daly ME, Kennedy EB,
Antonoff MB, Broderick S, Feldman J, Jolly S, Meyers B, Rocco G,
Rusthoven C, et al: Stereotactic body radiotherapy for early-stage
non-small-cell lung cancer: American society of clinical oncology
endorsement of the American society for radiation oncology
evidence-based guideline. J Clin Oncol. 36:710–719. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Claude L, Morelle M, Mahé MA, Pasquier D,
Boisselier P, Bondiau PY, Touboul E, Peignaux-Casasnovas K,
Martel-Lafay I, Gassa F, et al: A comparison of two modalities of
stereotactic body radiation therapy for peripheral early-stage
non-small cell lung cancer: results of a prospective French study.
Br J Radiol. 93:202002562020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar SS, Hall L, Li X, Downes L, Shearer
A, Shelton BJ, Gerring S and McGarry RC: Comparison of outcomes of
stereotactic body radiation therapy delivered with three different
technologies to the lung. J Radiosurg SBRT. 5:209–216.
2018.PubMed/NCBI
|
|
12
|
Guo Y, Zhu Y, Zhang R, Yang S, Kepka L,
Viani GA, Milano MT, Sio TT, Sun X, Wu H, et al: Five-year
follow-up after stereotactic body radiotherapy for medically
inoperable early-stage non-small cell lung cancer: A multicenter
study. Transl Lung Cancer Res. 12:1293–1302. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Swaminath A, Parpia S, Wierzbicki M,
Kundapur V, Faria S, Okawara GS, Tsakiridis TK, Ahmed N, Bujold A,
Hirmiz K, et al: Stereotactic vs hypofractionated radiotherapy for
inoperable stage I non-small cell lung cancer: The LUSTRE phase 3
randomized clinical trial. JAMA Oncol. 10:1571–1575. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Onishi H, Shioyama Y, Matsumoto Y, Matsuo
Y, Miyakawa A, Yamashita H, Matsushita H, Aoki M, Nihei K, Kimura
T, et al: Real-world results of stereotactic body radiotherapy for
399 medically operable patients with stage I histology-proven
non-small cell lung cancer. Cancers (Basel). 15:43822023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang JY, Mehran RJ, Feng L, Verma V, Liao
Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, et al:
Stereotactic ablative radiotherapy for operable stage I
non-small-cell lung cancer (revised STARS): Long-term results of a
single-arm, prospective trial with prespecified comparison to
surgery. Lancet Oncol. 22:1448–1457. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Onishi H, Shirato H, Nagata Y, Hiraoka M,
Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, et al:
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I
non-small cell lung cancer: updated results of 257 patients in a
Japanese multi-institutional study. J Thorac Oncol. 2 (7 Suppl
3):S94–S100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moreno AC, Fellman B, Hobbs BP, Liao Z,
Gomez DR, Chen A, Hahn SM, Chang JY and Lin SH: Biologically
effective dose in stereotactic body radiotherapy and survival for
patients with early-stage NSCLC. J Thorac Oncol. 15:101–109. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iovoli AJ, Prasad S, Ma SJ, Fekrmandi F,
Malik NK, Fung-Kee-Fung S, Farrugia MK and Singh AK: Long-term
survival and failure outcomes of single-fraction stereotactic body
radiation therapy in early stage NSCLC. JTO Clin Res Rep.
4:1005982023.PubMed/NCBI
|
|
19
|
Videtic GM, Paulus R, Singh AK, Chang JY,
Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans
KL, et al: Long-term follow-up on NRG oncology RTOG 0915 (NCCTG
N0927): A randomized phase 2 study comparing 2 stereotactic body
radiation therapy schedules for medically inoperable patients with
stage I peripheral non-small cell lung cancer. Int J Radiat Oncol
Biol Phys. 103:1077–1084. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lindberg K, Grozman V, Karlsson K,
Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA,
Moeller DS, et al: The HILUS-trial-A prospective nordic multicenter
phase 2 study of ultracentral lung tumors treated with stereotactic
body radiotherapy. J Thorac Oncol. 16:1200–1210. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosenberg SA, Mak R, Kotecha R, Loo BW Jr
and Senan S: The nordic-HILUS trial: Ultracentral lung stereotactic
ablative radiotherapy and a narrow therapeutic window. J Thorac
Oncol. 16:e79–e80. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eriguchi T, Takeda A, Nemoto T, Tsurugai
Y, Sanuki N, Tateishi Y, Kibe Y, Akiba T, Inoue M, Nagashima K and
Horita N: Relationship between dose prescription methods and local
control rate in stereotactic body radiotherapy for early stage
non-small-cell lung cancer: Systematic review and meta-analysis.
Cancers (Basel). 14:38152022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyasaka Y, Komatsu S, Abe T, Kubo N,
Okano N, Shibuya K, Shirai K, Kawamura H, Saitoh JI, Ebara T and
Ohno T: Comparison of oncologic outcomes between carbon ion
radiotherapy and stereotactic body radiotherapy for early-stage
non-small cell lung cancer. Cancers (Basel). 13:1762021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun JE, Kim S, Park KY and Lee W:
Effectiveness and safety of carbon ion radiotherapy in solid
tumors: A systematic review and meta-analysis. Yonsei Med J.
65:332–340. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buchberger DS and Videtic GMM:
Stereotactic body radiotherapy for the management of early-stage
non-small-cell lung cancer: A clinical overview. JCO Oncol Pract.
19:239–249. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ong CL, Palma D, Verbakel WARF, Slotman BJ
and Senan S: Treatment of large stage I–II lung tumors using
stereotactic body radiotherapy (SBRT): Planning considerations and
early toxicity. Radiother Oncol. 97:431–436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barriger RB, Forquer JA, Brabham JG,
Andolino DL, Shapiro RH, Henderson MA, Johnstone PA and Fakiris AJ:
A dose-volume analysis of radiation pneumonitis in non-small cell
lung cancer patients treated with stereotactic body radiation
therapy. Int J Radiat Oncol Biol Phys. 82:457–462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang JY, Liu H, Balter P, Komaki R, Liao
Z, Welsh J, Mehran RJ, Roth JA and Swisher SG: Clinical outcome and
predictors of survival and pneumonitis after stereotactic ablative
radiotherapy for stage I non-small cell lung cancer. Radiat Oncol.
7:1522012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Wang W, Shiue K, Yao H,
Cerra-Franco A, Shapiro RH, Huang KC, Vile D, Langer M, Watson G,
et al: Risk factors for symptomatic radiation pneumonitis after
stereotactic body radiation therapy (SBRT) in patients with
non-small cell lung cancer. Radiother Oncol. 156:231–238. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kita N, Tomita N, Takaoka T, Okazaki D,
Niwa M, Torii A, Takano S, Mekata Y, Niimi A and Hiwatashi A:
Clinical and dosimetric factors for symptomatic radiation
pneumonitis after stereotactic body radiotherapy for early-stage
non-small cell lung cancer. Clin Transl Radiat Oncol.
41:1006482023.PubMed/NCBI
|
|
31
|
Mino-Kenudson M: Significance of tumor
spread through air spaces (STAS) in lung cancer from the
pathologist perspective. Transl Lung Cancer Res. 9:847–859. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia M, Yu S, Gao H and Sun PL: Spread
through air spaces (STAS) in lung cancer: A multiple-perspective
and update review. Cancer Manag Res. 12:2743–2752. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shih AR and Mino-Kenudson M: Updates on
spread through air spaces (STAS) in lung cancer. Histopathology.
77:173–180. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suh YJ, Han K, Kwon Y, Kim H, Lee S, Hwang
SH, Kim MH, Shin HJ, Lee CY and Shim HS: Computed tomography
radiomics for preoperative prediction of spread through air spaces
in the early stage of surgically resected lung adenocarcinomas.
Yonsei Med J. 65:163–173. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Neacşu F, Vârban AŞ, Simion G, Şurghie R,
Pătraşcu OM, Sajin M, Dumitru M and Vrînceanu D: Lung cancer
mimickers-a case series of seven patients and review of the
literature. Rom J Morphol Embryol. 62:697–704. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
POSTILV, . A randomized phase II trial in
patients with operable stage I non-small cell lung cancer: Radical
resection versus ablative stereotactic radiotherapy. RTOG
Foundation. Available from:. https://www.rtog.org/Clinical-Trials/Foundation-Studies/3502October
7–2024
|
